Evidence map›Paper›PMID 39520637›Full record

ReviewInternational urology and nephrology2025

Mesenchymal stem cell-derived exosomes in renal ischemia-reperfusion injury: a new therapeutic strategy.

Bo Zhao, Zhenwang Zhang, Xiying Guo, Xiufen Liu, Min Lei, Shuang Guo, Qing Yao, Feixue Zhang, Tie Peng, Aimei Liu and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bo Zhao *Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Zhenwang Zhang *Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Xiying Guo *Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Xiufen Liu *Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Min LeiHubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Shuang GuoHubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Qing YaoHubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Feixue ZhangHubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Tie PengHubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China.
Aimei LiuHubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China. liuaimei@hbust.edu.cn.
Botao JiangXianning Central Hospital, First Affiliated Hospital of Hubei University of Science and Technology , 228 Jingui Road, Xian'an District, 437000, Xianning, Hubei Province, People's Republic of China. doctorjbt@163.com.
Dan ZhuHubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, No.88, Xianning Avenue, Xianan District, 437000, Xianning, Hubei Province, People's Republic of China. zhudan@hbust.edu.cn.

Funding

Foundation of Hubei University of Science and Technology "Doctoral Initiation Fund" BK202414Foundation of Hubei University of Science and Technology "Horizontal Research Projects" 2023HX121Hubei University of Science and Technology "Medical Research Special Fund" 2022YKY18Natural Science Foundation of Hubei Province 2024AFB1025
6 · The paper itself

Abstract

Renal ischemia-reperfusion injury (RIRI) is a serious kidney condition that causes significant damage due to lack of blood flow. This injury leads to oxidative stress and inflammation, which can cause acute tubular necrosis and kidney failure. Stem cell-derived exosomes, small vesicles released by stem cells, have shown promise in treating RIRI. Mesenchymal stem cells (MSCs) have been used to mitigate RIRI, and their exosomes have been found to play a crucial role in repairing damaged tissues. This review explores the key roles of exosomes from different sources of MSCs in RIRI, the potential of MSC-derived exosomes in treating this disease, and future research directions.

Indexed as

ExosomesKidneyMesenchymal Stem CellsMesenchymal Stem Cell TransplantationReperfusion InjuryAcute Kidney InjuryAnimalsHumansExosomesMesenchymal stem cellsRIRIStem cellsTherapy

Identifiers

PMID39520637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.